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study question: Does the use of a digital home ovulation test have any effect on the level of stress in women seeking to conceive?
summary answer: No difference was found in levels of stress between women using digital ovulation tests to time intercourse com-
pared with women who were trying to conceive without any additional aids: in addition, their use did not negatively impact time to concep-
tion in users but may provide additional beneﬁts, including an increased understanding of the menstrual cycle, reassurance and conﬁdence in
focusing conception attempts to the correct time in the cycle.
what is known already: It has been suggested that timing of intercourse in such a way that it coincides with ovulation by using
ovulation tests can lead to emotional distress; however, no study has been conducted to investigate this hypothesis speciﬁcally, until now.
study design, size and duration: The study was performed over two complete menstrual cycles as a prospective, rando-
mized, controlled trial including quantitative and qualitative methods. The intervention (test) group were given digital ovulation tests to time
intercourse to the most fertile time of the cycle and the control group were provided with the current National Institute for Health and
Clinical Excellence guidelines for increasing the chances of conception (intercourse every 2–3 days) and asked not to use any additional
methods to time when ovulation occurs.
participants/materials, setting and methods: A total of 210 women who were seeking to conceive were recruited
from the general UK population. A total of 115 women were randomized to the test group and 95 to the control group through block random-
ization. The positive and negative affect schedule (PANAS) and the Perceived Stress Scale (PSS) were used to measure subjective stress levels, the
Short-Form 12 health survey was used as a measure of general health and well-being and urine samples were measured for biochemical markers
of stress including urinary cortisol. Qualitative data were collected in the form of a telephone interview upon study completion.
main results and the role of chance: There was no evidence for a difference either in total stress as measured using the PSS
or in total positive or negative affect using the PANAS questionnaire between the test and control groups at any time point for the duration of the
study. During cycle 1, for example, on Day 6, the difference in total stress score (test–control) was 20.62 [95% conﬁdence interval (CI) 22.47
to 1.24] and on the day of the LH surge, it was 0.53 (95% CI 21.38 to 2.44). In addition, no correlation was observed between time trying to
conceive and levels of stress, or between age and levels of stress, and no evidence was found to show that stress affected whether or not a
pregnancy was achieved. There is also no evidence that the biochemistry measurements are related to whether a pregnancy was achieved or
of a difference in biochemistry between the treatment groups. The use of digital ovulation tests did not negatively affect time to conception
and with an adequately sized study, could potentially show improvement. To ensure that the results of this study were not affected by
chance, we used a number of different methods for measuring stress, each of which had been independently validated.
limitations and reasons for caution: Randomization occurred before the start of the study because of the need to provide
the ovulation tests in readiness for Day 6 of the ﬁrst cycle. As a consequence, a number of women fell pregnant during this period (22 and 13 in
the test and control groups, respectively). A further 15 women were either lost to follow-up or withdrew consent prior to study start. Pregnancy
rate was higher overall in the test group, so to ensure that there were sufﬁcient data from women who failed to become pregnant in the test
group, we implemented an additional biased recruitment. This second cohort may have been different from the ﬁrst, although no signiﬁcant dif-
ferences were observed between the two phases of recruitment for any of the information collected upon admission to the study.
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wider implications of the findings: Women who seek medical advice while trying to conceive should not be discouraged by
health care professionals from using digital ovulation tests in order to time intercourse. The cohort of women recruited to this study initially had
no evidence of infertility and were looking to conceive in a non-medical setting. A separate study to assess the impact of home ovulation tests in a
subfertile population would be of interest and complementary to the present study.
study funding/competing interests: This study was funded by SPD Swiss Precision Diagnostics, GmbH, manufacturer of
Clearbluew pregnancy and ovulation tests. SPD Development Company Ltd is a wholly owned subsidiary of SPD Swiss Precision Diagnostics
GmbH; together referred to as SPD.
trial registration number: NCT01084304 (www.clinicaltrials.gov).
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Introduction
Becoming pregnant is often not straightforward and it has been esti-
mated that one in seven couples in the UK suffer from difﬁculty in con-
ceiving (NICE, 2004). There are a myriad of causes for failing to
conceive quickly, but a simple factor that is easily corrected is ensuring
that intercourse occurs during the fertile window. Conception is most
likely to occur when intercourse takes place on the day before or on
the day of ovulation (Wilcox et al., 2000) and studies have shown that
with fertility-focused intercourse, conception is likely to occur more
quickly (Hilgers et al., 1992; Gnoth et al. 2002; Stanford, et al.,
2002; Robinson et al., 2007). There are two main reasons why
couples may incorrectly time intercourse, ﬁrstly because they are
unaware of the most appropriate time in their cycle (Zinaman et al.,
2012) and secondly, the clinical prediction that the fertile window
usually occurs between Days 10 and 17 of the menstrual cycle is
often not correct (Wilcox et al., 2000; Stanford et al., 2002; Robinson
and Ellis, 2007). This is because although normally cycling women have
a mean cycle length of 27–28 days, the range both within and
between individuals is considerably longer and has been reported to
be as high as 36 days (Creinen et al., 2004; Johnson et al., 2009).
Home ovulation tests are a simple and popular method for timing
intercourse via the daily monitoring of urinary LH levels in order to
detect the LH surge that occurs 24–36 h prior to ovulation
(WHO, 1980; Singh et al., 1984; Collins, 1985; Behre et al., 2000).
It has been suggested that timing of intercourse so as to coincide it
with ovulation by using ovulation tests or other fertility awareness-based
methods can lead to emotional distress. The current National Institute
for Health and Clinical Excellence (NICE) guidelines state that couples
who are concerned about their fertility should be informed that sexual
intercourse every 2–3 days optimizes the chances of pregnancy. The
guidelines also state that timing of intercourse so as to coincide it with
ovulation causes stress and is not recommended (NICE, 2004). The evi-
dence supporting this statement in the guidelines is limited to a retro-
spective observational study of 26 patients undergoing infertility
treatment, where it was found that events associated with lack of con-
ception or loss of pregnancy, such as a negative pregnancy test, onset
of menses, ectopic pregnancy or miscarriage, were in fact emotionally
more difﬁcult (Kopitzke et al., 1991). Indeed, failure to become pregnant
is likely to be the greatest cause of stress when a woman is trying to con-
ceive (Severy et al., 2006). It is also reasonable to suggest that attempts
to undertake frequent intercourse for the duration of the cycle (NICE,
2004) may prove excessively demanding and thus as emotionally challen-
ging as timing intercourse to the fertile period.
The advancement in ease of use and accuracy of home ovulation
test devices, in particular the introduction of digital displays, means
that women now ﬁnd it easier to interpret the results of these
tests, which can in turn lead to greater certainty (Johnson et al.,
2011). In addition, many women have a poor understanding of their
menstrual cycle and the timing of ovulation (Zinaman et al., 2012).
Home ovulation test devices can help build awareness and knowledge
of oneself during attempts to conceive as well as help to empower and
engage women to take control of their own fertility (Brown et al.,
1987; Blackwell et al., 2003).
We conducted this study in response to the misunderstanding and
confusion surrounding whether such products promote stress. The
aim of this study was to compare levels of stress in women seeking
to conceive while using digital home ovulation tests compared with
women who were provided with the NICE clinical guidelines on in-
creasing the chances of conception. We hypothesized that there
would be no measurable difference in the level of stress associated
with either method of trying to conceive as for both intercourse is
determined by instruction and not necessarily by choice.
Stress and negative emotions can be expressed via biochemical
and/or behavioural channels, which allow them to be measured in a
number of ways including psychological questionnaires, biochemical
markers and qualitative interview techniques. Questionnaires are
useful tools to measure subjective phenomena such as symptoms
and quality of life and biomarkers are chemical indicators of biological
state. Both are useful tools for measuring baseline information and in
evaluating change over time while qualitative techniques are useful in
exploring common themes arising from in-depth discussions. Cortisol
is a well-established biomarker associated with increased levels of
stress (Miki and Sudo, 1998; Nicolson, 2008; Nepomnaschy et al.,
2011), and there are several psychological questionnaires that are
well-validated and commonly used for observing both speciﬁc and
non-speciﬁc stress in clinical settings. All three of these measures
were incorporated into this randomized, controlled study.
Materials and Methods
Study design and recruitment
The study was performed as a prospective, randomized controlled trial in-
cluding quantitative and qualitative methods. The study protocol was
approved by SPD ethics committee. Volunteers were recruited via an
advert placed on the Clearblue UK website, which attracted 550
responses. Detailed information about the study was provided to the
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volunteers and written informed consent was obtained before the com-
mencement of the study.
A total of 210 volunteers were recruited from the UK population (21
February–5 December 2010). The inclusion criteria were women living
in the UK who were aged between 18 and 40 years, having regular men-
strual bleeds and wishing to become pregnant. Excluded were women
who had been using hormonal contraception in the last 3 months,
women currently undergoing fertility treatment or investigation, women
who had previously been diagnosed as infertile, anyone with a history of
depression, anxiety or panic attacks and anyone dependant on either
drugs or alcohol. Women who had previously used ovulation tests were
not excluded from participating in the study.
Study population, sample size and
randomization
Since the variability of stress was unknown, a pragmatic decision was taken
to recruit 75 subjects per group, which was feasible in the time period and
would give 80% power to detect a difference of 0.4 SDs at 5% signiﬁcance
level, which is a moderate effect size. Kopitzke et al. (1991) demonstrated
a difference in stress in women trying to conceive based on a sample size
of 26. Initially, 150 volunteers were recruited to the study and these were
randomized equally either into the test or into the control group through
block randomization. Test-group volunteers used the Clearblue Digital
Home Ovulation Test for the duration of the study. They were asked to
begin testing on Day 6 of their cycle regardless of their normal cycle
length. Control-group volunteers were asked not to identify their time
of ovulation using methods such as ovulation testing or basal body tem-
perature measurements and instead were advised of the NICE guidelines
on how to increase the chances of conception, i.e. that sexual intercourse
every 2–3 days for the duration of the cycle is likely to increase the
chances of conception. It was the volunteers’ choice as to whether or
not they followed these guidelines. On completion of the study, the
control-group volunteers were provided with Clearblue Digital Home
Ovulation Tests as an incentive for complete participation.
Upon completion of the study by the initial 150 volunteers, it was found
that there were more pregnancies than expected (44 and 26 in total for
the test and the control groups, respectively). This resulted in fewer ques-
tionnaires and urine samples being available from ovulation test users who
failed to become pregnant while on the study, so that there was insufﬁcient
power to ascertain a true representation of levels of stress in this group
compared with the control group. Therefore, an additional cohort (60
volunteers in total) was recruited in the same way as the main study,
only randomization was weighted at a ratio of 2:1 into the test group in
order to enrich the data in this group. This resulted in a ﬁnal study popu-
lation of 210 volunteers with 115 randomized to the test group and 95 to
the control group.
Randomization schedules were generated using the STATA software by
a statistician who was not directly involved in the recruitment of the study.
Un-blinding of the study did not take place until statistical analysis of the
data was complete.
Study protocol
Upon admission to the study, a brief medical history was collected from
each volunteer, including demographic information, obstetric and gynaeco-
logical history as well as information regarding their general health. Once
recruited, volunteers were assigned to a randomization group by the study
co-ordinator, sent the required study materials and asked to begin in their
next menstrual cycle. For some volunteers, this resulted in a pregnancy
being achieved prior to the start of Cycle 1. These were known as ‘Pre-
cycle 1 pregnancies’. Volunteers were asked to collect ﬁrst morning
urine samples and to complete a range of questionnaires at speciﬁc time
points over two complete menstrual cycles according to the schedule pre-
sented in Fig. 1. Levels of stress were determined both biochemically and
by questionnaire. The additional measurement at time point 6 in Cycle 3
was included to ensure that all participants completed two full cycles,
while on the study and to ensure that pregnancy rate in Cycle 2 could
be captured. This time point also allowed levels of stress to return to base-
line where necessary after receiving the news that pregnancy had not been
achieved after two cycles of trying to conceive while on the study.
Quantitative data collection
The questionnaires used were the Perceived Stress Scale (PSS) (Cohen
et al, 1983), the positive and negative affect schedule (PANAS) (Watson
et al., 1988) and the Short Form-12 Health Survey (SF-12) (Ware and
Sherbourne, 1992). The biochemical marker of stress was urinary cortisol,
which is a well-established stress indicator (Nakamura et al., 2008). In add-
ition, urinary estrone-3-glucuronide (E3G) was analysed as a marker of es-
trogen status as levels of this marker are known to be associated with
depression and anxiety (Lokuge et al., 2011).
The PSS questionnaire is a measure of the degree to which situations in
one’s life are appraised as stressful. Items were designed to highlight how
unpredictable, uncontrollable and overloaded respondents ﬁnd their lives.
The instrument uses a 5-point Likert scale rating from ‘0 ¼ never’ to ‘4 ¼
very often’. Scores can range from 0 to 40, with higher scores indicating a
higher level of perceived stress (Cohen et al., 1983). The mean score for a
normative sample of females completing the PSS questionnaire is 13.7+
6.6 (Cohen and Williamson, 1998).
The PANAS questionnaire consists of 10 positive affects (PA), (inter-
ested, excited, strong, enthusiastic, proud, alert, inspired, determined, at-
tentive and active) and 10 negative affects (NA), (distressed, upset, guilty,
scared, hostile, irritable, ashamed, nervous, jittery and afraid). Participants
are asked to rate items on a scale from 1 to 5, on the basis of the strength
of emotion where ‘1 ¼ very slightly or not at all’ and ‘5 ¼ extremely’. For
both of the PANAS domains, scores can range between 10 and 50. A
higher score on the positive domain indicates greater PA (e.g. they are
happier). However, a higher score on the negative domain indicates
greater NA (e.g. they are more depressed) (Watson et al., 1988). The val-
idity and reliability of the PANAS questionnaire and its relationship
between other measures of depression and anxiety was determined by
Crawford and Henry (2004) where the mean score for a normative
sample of females completing the PANAS questionnaire was 30.62 (SD
7.89) for PA and 16.68 (SD 6.37) for NA. The PSS and PANAS question-
naires were completed at time points 1–6 as shown in Fig. 1.
Finally, the SF-12 is a brief, well-validated and reliable generic question-
naire for capturing general health status and outcome information. The
SF-12 health survey is one of the most widely cited measures of functional
health status. The UK female population have been found to have scores
of 49.54 and 49.17 for the physical and mental attributes, respectively,
using the SF-36 version 2 questionnaire (Jenkinson et al., 1999). The
SF-12 questionnaire used in this study has been shown to yield comparable
scores with the SF-36 questionnaire in both general and speciﬁc popula-
tions. It was completed at baseline (time point 1) by all study volunteers
and again at the end of the study (time point 6) only by the volunteers
who did not get pregnant.
First morning urine samples were collected at time points 2–6 using
sample collection pots containing sodium azide as a preservative. Upon
receipt of samples at the study site, they were added to a central
sample database, aliquoted and stored at 2808C until analysis. All the
urine samples were analysed for cortisol and E3G using fully validated im-
munoassay systems and normalized for urine volume using creatinine
measurements.
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Cortisol was measured using the Access 2 auto-analyser system from
Beckman Coulter (High Wycombe, UK). The sensitivity of this urine
assay is 0.4 mg/dl (11 nmol/l). Intra-assay % coefﬁcient of variance
(CV)s were 6.7, 4.4 and 4.4 and inter-assay %CVs were 7.9, 6.0 and 6.4
at low, medium and high concentrations, respectively. E3G analysis was
carried out using a competitive immunoassay that was developed for
urine samples by SPD for use on the DELFIA auto-analyzer system from
Perkin Elmer (Waltham, Massachusetts) (Miro et al., 2005). The sensitivity
of this urine assay is 0.076 ng/ml. Intra-assay %CVs were 2.1, 2.0 and 2.5
and inter-assay %CVs were 0.7, 0.9 and 1.0 at low, medium and high con-
centrations, respectively. Creatinine analysis was also carried out to enable
volume correction of the markers indicative of stress. This measurement
was made using the ABX Pentra 400 analyser from Horiba (Kyoto,
Japan). The sensitivity of this urine assay is 1.39 mg/dl (123 mmol/l).
Figure 1 Schedule of events and numbers of volunteers at each time point during the study. In total, 354 women were able to be contacted to
participate in the study. Of those, 255 volunteers were eligible to participate and 45 did not return their consent. This left a ﬁnal study population
of 210. Reasons for withdrawal from the study include: no longer trying to conceive (n ¼ 6), unable to carry out the study (n ¼ 4), health reasons
(n ¼ 10), protocol violation (n ¼ 3), unwanted randomization to the control group (n ¼ 2) and no reason given (n ¼ 2). LTFU, lost to follow-up
(n ¼ 19). *1 volunteer did not provide complete data prior to randomization. Day of predicted ovulation for the control group was based on self-
reported average cycle length information collected upon admission to the study.
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Intra-assay %CVs were 3.3, 0.6 and 0.5 and inter-assay %CVs were 6.0,
1.9 and 1.8 at low, medium and high concentrations, respectively.
Qualitative data collection
Upon completion of the study, individual, semi-structured telephone inter-
views were carried out with all the study participants to gain feedback on
the use of the ovulation test, attitude to trying to conceive and further
insight into their emotional wellbeing. The interview schedule comprised
of both closed and open-ended questions. Interviews ranged from 10 to
30 min in length.
Data analysis of the interviews was carried out using a thematic ap-
proach (Marshall and Rossman, 1999), which is widely used in qualitative
research. This enables data sources to be analysed in terms of the principal
concepts or themes. These themes were then developed by the analyst,
to enable the data to be reduced to key ideas.
Statistical analysis
The standardized psychological questionnaires (PSS, PANAS and SF-12)
were coded following the scoring systems for each instrument and sum-
marized using descriptive statistics. Mean questionnaire scale scores for
the volunteers were given for each time point. Summary measures were
used to examine the proﬁle of stress over time between the baseline
and remaining time point assessments (Matthews et al., 1990). A
mixed-effects model was applied to the scores over time. Sensitivity ana-
lyses were also performed to check the robustness of the conclusions,
given the nature and number of missing data values in this study. Imput-
ation methods were used to assess the effect of missing data due to attri-
tion. Logistic regression was used to assess whether biochemical and
psychological measures of stress can predict whether a subsequent con-
ception will occur. Log transformation of the biochemical marker mea-
surements was conducted to stabilize variance. The demographic data
captured at recruitment were also analysed to examine the inﬂuence of
age and time spent trying to conceive on stress levels over the duration
of the study.
A principal components analysis (PCA) was also applied to the stress
scores and to the biochemical measures of stress, categorizing the subjects
on their demographic characteristics. Finally, Kaplan–Meier analysis was
used to estimate time-to-event (i.e. conception) distributions in the two
treatment groups and odds ratios were calculated.
Results
Study population
The mean age of 210 volunteers participating in the study was
28.87 years (range:19–40). The mean self-reported menstrual
cycle length was 30.54 days (range: 25–49) and on average the
study volunteers had been trying to conceive for 8.7 months
(range: 0–84). Table I shows the various demographic variables
by randomization group.
All the 210 women were randomized and of these 35 (16.7%) did
not begin the study because of becoming pregnant prior to the start of
Cycle 1 ‘Pre-cycle 1 pregnancy’ and a further 20 withdrew from the
study or were lost to follow-up before the study started as detailed
in Fig. 1. Of the remaining 155 volunteers, 87 (56.1%) completed
the study without achieving a pregnancy and 42 (27.1%) achieved a
pregnancy either during Cycle 1 (n ¼ 29) or during Cycle 2 (n ¼
13). The remaining 26 (16.8%) volunteers were lost to follow-up or
withdrew from the study for various reasons as detailed in Fig. 1.
During recruitment, over a quarter of volunteers (28.1%) believed
their cycle length to be the text book 28 days. Data available from
all the volunteers up until the point at which they left the study
were used.
Pregnancy rates
Table II gives the outcomes of the study by pregnancy status or with-
drawal. For those randomized, 43% achieved a pregnancy in the test
group, compared with 30% in the control. Excluding those who
became pregnant and who were lost to follow-up before the start
of the study, the rates were 31% and 22% for the test and the
control groups, respectively. Kaplan–Meier estimates of time-to-event
(i.e. conception) are shown in Figs 2 and 3 for all the subjects
(intention-to-treat analysis) and for the subjects present at the start
of the study (per protocol analysis) respectively.
Odds ratio was calculated for women who completed the study,
excluding Pre-cycle 1 pregnancy individuals and those who were lost
to follow-up prior to the start of the study. This analysis showed
that the odds of getting pregnant in the test group was 1.59 [95% con-
ﬁdence interval (CI): 0.7652, 3.038] compared with the control group.
Analysing the full study population (intention-to-treat), the odds of
getting pregnant in the test group were found to be 1.77 (95% CI:
0.9992, 3.1585) compared with the control group.
Levels of stress as measured by questionnaire
In order to analyse the questionnaire data, comparisons were made
between the women in the test group and those in the control
group. Volunteers were categorized according to outcome: those
who completed the study without getting pregnant, those who got
pregnant in Cycle 1 of the study, those who got pregnant in Cycle 2
of the study, those who got pregnant before the study began and
those who were exited from the study for other reasons, such as with-
drawn consent or lost to follow-up (this outcome was labelled
‘other’). Logistic regression analysis was used to assess whether
stress can predict pregnancy. Results were analysed for total stress,
which was determined using the PSS and for total PA and NA as
determined by the PANAS questionnaire.
Table III shows summary statistics for total stress and total PA and
NA scores at all time points of the study. There was no evidence of a
difference in total stress, total PA or total NA between the test and
the control groups or between the different outcome groups and
no evidence of a change in levels over time. This ﬁnding was also sup-
ported by the PCA, which found no substantive relationships between
randomization group, study outcome, time point or any indices of
stress measured.
Figure 4 shows PCA analysis of the ﬁrst two components ﬁtted to
all the data, including all the questions from the questionnaires, the
demographic characteristics and the biochemical markers, identiﬁed
by measurement type and labelled by time point. The ﬁrst component
identiﬁed a trend that is explained by the ‘positive’ and ‘negative’ ques-
tions/responses to the PANAS and PSS questionnaires and the
second component identiﬁed a difference (or separation) between
the SF-12 questions/responses and the other measurements. The
‘positive’ questions were negatively correlated with the ‘negative’
questions and appear on opposite sides of the graph. The questions
from the SF-12 scale were grouped in the bottom half of the graph;
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the ‘positive’ questions were grouped together in the bottom left
quadrant of the graph and the ‘negative’ questions were grouped to-
gether around the middle and to the left of the graph.
SF-12 scores are split into physical and mental attributes and
summary statistics are also presented in Table III. No difference was
found for either mental or physical attributes at time point 6
between the two randomization groups. In fact, the ﬁgures were
similar for the test and control groups at the end of the study in the
mean mental component (46.40 and 46.15, respectively) and the
mean physical component (41.86 and 41.12, respectively).
The correlation between total stress and length of the time trying to
conceive was also analysed at the start of the study as it was possible
that a longer time in trying to conceive could lead to a higher level of
stress. Results showed that for all time points the correlation was posi-
tive, but very low. The PCA did not support a correlation between
stress and time trying to conceive. When analysing other demographic
data collected upon admission, no correlation was observed between
total stress and age, number of previous pregnancies or miscarriages,
and no evidence was found to show that stress affects whether or not
a pregnancy will be achieved.
Levels of stress as measured by biochemical
marker
Figure 5 is the PCA analysis of the ﬁrst two components ﬁtted to all
the data, except the individual questions, focusing on the biochemical
markers, identiﬁed by measurement type and labelled by time point.
There was no clear separation between the two randomization
groups or between outcomes in either of the ﬁrst two components
ﬁtted. The ﬁrst component related to the stress score identifying a
trend that is explained by the ‘positive’ and ‘negative’ questions/
responses. The second component related to the correlations
between the biochemical markers.
There was no evidence of a relationship between the demographic
characteristics and outcome or treatment group, with the exception of
alcohol consumption. High alcohol consumption was associated with
the biochemistry measurements but only in a very few volunteers.
The means and standard deviations of the ratio of cortisol to cre-
atinine and E3G to creatinine, over time, for the test and the
control groups (samples were collected at time points 2–6) can be
................................................................... ..................................................................
.............................................................................................................................................................................................
Table I Demographic variables by randomization group (mean, median and range except where indicated).
Test group (n5 115) Control group (n 5 95)
Mean Median (SD) Range Mean Median (SD) Range
Total previous pregnancies 1.7 1 0–7 1.8 2 0–7
Total live births 0.95 1 0–4 1.11 1 0–7
Total miscarriages 0.79 0 0–5 0.57 0 0–4
Months trying to conceive 8.6 6 0–60 8.8 6 1–84
Cycle length (days) 30.56 29 25–49 30.57 30 25–46
Height (m) 1.65 (0.071) 1.42–1.80 1.65 (0.066) 1.46–1.83
Weight (kg) 73.7 (15.82) 49.9–114.3 73.1 (18.92) 47.6–173.0
BMI (kg/m2) 26.9 25.6 17.47–43.82 26.8 24.6 17.58–59.86
Alcohol (units/week) 2.41 0.50 0–15 2.11 0 0–10
Exercise (h/week) 3.0 2 0–20 3.5 3 0–21
Age (years) 28.3 28 20–40 29.7 30 19–39
Pre-cycle 1 Period (days) 30.76 23 9–243 29.75 27 5–127
Smoking History
Yes 10 (8.7%) 4 (4.2%)
Ex 30 (26.1%) 45 (21.4%)
No 75 (65.2%) 76 (80.0%)
Previous ovulation test use
Yes 59 (51.3%) 60 (63.2%)
No 56 (48.7%) 35 (36.8%)
........................................................................................
Table II Breakdown of volunteer outcome by
pregnancy or withdrawal.
Frequency
(column% age)
Test group
(%)
Control
group (%)
Total
Withdrew from Study 13 (11.30) 14 (14.74) 27
Lost to follow-up 9 (7.83) 10 (10.53) 19
Not pregnant 44 (38.26) 43 (45.26) 87
Pre-cycle 1 Pregnancy 22 (19.13) 13 (13.68) 35
Pregnant Cycle 1 20 (17.39) 9 (9.47) 29
Pregnant Cycle 2 7 (6.09) 6 (6.32) 13
Total 115 95 210
Pre-cycle 1 pregnancy—pregnancy achieved during cycle of consent, i.e. between
consenting to the study and before starting Cycle 1.
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Figure 2 Kaplan–Meier estimate of time to conception for all volunteers recruited to the study with 95% conﬁdence limits represented by the pink
and blue areas surrounding the lines. Time to conception is based on time from recruitment to the study. Censored data indicate women who are lost
to follow-up, for any reason, at the time indicated. Numbers at risk in each randomization group are given along the x-axis. Attrition of volunteers is
due either to achieving a pregnancy or to completion of study.
Figure 3 Kaplan–Meier estimate of time to conception for volunteers excluding those that exited the study prior to Cycle 1. The 95% conﬁdence
limits are represented by the pink and blue areas surrounding the lines. Time to conception is based on time from recruitment to the study. Censored
data indicate women who are lost to follow-up, for any reason, at the time indicated. Numbers at risk in each randomization group are given along the
x-axis. Attrition of volunteers is due either to achieving a pregnancy or to completion of study.
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found in Table III. The cortisol-to-creatinine ratio (and cortisol levels
alone) was found to be generally higher in the control group over
the test group (however, the data were highly correlated). There was
a difference in variability at the different time points; the E3G data
were more variable at surge times than Day 6 and concentrations
were higher on the surge days in the test group compared with the
control group. There appeared to be no relationship between total
stress and endocrine levels throughout the study and no evidence of
a relationship between pregnancy and endocrine levels in this sample
of subjects.
Qualitative data analysis
A random selection of 30 (15 from each randomization group) exit
interviews were used for analysis. The qualitative data collected
................................... .................................
.............................................................................................................................................................................................
Table III Summary statistics (means and SDs) for all measurements at all time points; total stress (PSS), total positive
and negative affect (PANAS), physical and mental attributes (SF-12) and cortisol: creatinine and E3G:creatinine ratios.
Total stress Test Control Difference test-control 95% CI
n Mean SD n Mean SD
T1—Baseline 114 14.99 4.58 93 14.80 5.10 0.19 21.15 to 1.54
T2—Cycle 1, Day 6 81 16.11 4.92 63 16.73 6.04 20.62 22.47 to 1.24
T3—Cycle 1, Surge Day 73 16.79 4.86 61 16.26 6.08 0.53 21.38 to 2.44
T4—Cycle 2, Day 6 52 17.29 6.00 51 16.10 5.49 1.19 21.06 to 3.44
T5—Cycle 2, Surge Day 48 17.25 5.43 47 15.23 5.38 2.02 20.19 to 4.22
T6—Cycle 3 37 17.76 6.48 40 15.78 6.25 1.98 20.91 to 4.87
Negative affect
T1—Baseline 113 14.16 4.03 93 14.37 4.58 20.21 21.41 to 0.99
T2—Cycle 1, Day 6 82 16.29 5.76 62 16.84 6.64 20.55 1.06 to 22.64
T3—Cycle 1, Surge Day 73 15.85 5.02 62 15.39 5.02 0.46 0.87 to 21.25
T4—Cycle 2, Day 6 51 18.37 6.17 50 17.44 6.16 0.93 1.23 to 21.50
T5—Cycle 2, Surge Day 47 16.62 6.21 47 16.28 6.60 0.34 1.32 to 22.28
T6—Cycle 3 38 17.55 6.97 40 16.90 6.64 0.65 1.54 to 22.42
Positive affect
T1—Baseline 114 36.14 7.00 92 37.96 6.26 21.82 23.64 to 0.01
T2—Cycle 1, Day 6 82 32.52 7.06 62 32.16 8.72 0.36 22.32 to 3.05
T3—Cycle 1, Surge Day 72 32.58 8.06 62 34.63 7.55 22.05 24.72 to 0.62
T4—Cycle 2, Day 6 50 31.16 8.71 50 33.04 8.16 21.88 25.22 to 1.47
T5—Cycle 2, Surge Day 47 31.55 8.50 47 34.28 7.78 22.73 26.06 to 0.61
T6—Cycle 3 36 29.75 10.24 38 34.26 8.06 24.51 28.80 to 20.22
SF-12
Physical T1—Baseline 115 39.80 3.53 93 39.65 3.28 0.15 20.78 to 1.10
Physical T6—Cycle 3, Day 6 38 41.86 4.00 40 41.12 3.14 0.74 20.87 to 2.37
Mental T1—Baseline 115 49.57 3.89 93 48.42 4.50 1.15 0.01 to 2.31
Mental T6—Cycle 3, Day 6 38 46.40 7.15 40 46.15 5.11 0.25 22.54 to 3.04
Cortisol (mg/dl):Creatinine (g/dl)
T2—Cycle 1, Day 6 84 136.29 62.82 66 157.23 138.92 220.94 257.35 to 15.46
T3—Cycle 1, Surge Day 69 129.15 70.36 61 149.04 85.20 219.89 247.22 to 7.44
T4—Cycle 2, Day 6 51 147.68 110.30 44 147.57 89.59 0.11 240.63 to 40.85
T5—Cycle 2, Surge Day 47 127.75 65.42 45 149.16 92.40 221.41 254.70 to 11.88
T6—Cycle 3 37 139.33 59.03 38 156.23 89.44 216.9 251.69 to 17.89
E3G (ng/ml):Creatinine (g/dl)
T2—Cycle 1, Day 6 84 98.99 56.69 66 101.34 46.23 22.35 218.94 to 14.26
T3—Cycle 1, Surge Day 69 403.15 237.43 61 276.31 180.57 126.84 54.10 to 199.58
T4—Cycle 2, Day 6 51 104.90 79.52 44 108.32 56.13 23.42 231.19 to 24.35
T5—Cycle 2, Surge Day 47 311.11 206.71 45 261.54 182.65 49.57 231.14 to 130.28
T6—Cycle 3 37 101.59 52.34 38 95.24 52.43 6.35 217.76 to 30.46
The number of evaluable data points may not match those in Fig. 1 because of missing or incomplete questionnaires at speciﬁc time points.
(E3G, estrone-3-glucuronide).
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during the exit interview offered a deeper insight into the thoughts and
feelings of the individuals who took part in the study. Results from
closed questions in which the answers could be tabulated can be
found in Table IV. These results highlight that many women expected
to get pregnant within a short time frame, 56.7% stating that they
would have expected to achieve a pregnancy either quickly or
within 6 months of starting to try. It also highlighted that many
women had little knowledge of the length of their cycles or when
they were ovulating, 66.67% stating that before joining the study
they had no idea of when they were ovulating. In addition, 53% of
those analysed from the test group felt that they had a better under-
standing of changes occurring in their bodies around the time of ovu-
lation after using the digital ovulation tests during the study.
Of the volunteers in the control group who were provided with the
NICE guidelines for increasing chances of conception, 80% chose to
follow them when asked during the exit interview. Those that chose
not to follow these guidelines did so because of the perceived
added pressure or inconvenience. All the interviewees found the
digital ovulation tests easy to use and understand, often comparing
them with the visual read tests, which they reported as being
difﬁcult to read.
Some of the perceived advantages and disadvantages of using the
digital ovulation tests mentioned by volunteers during the exit inter-
view have been listed and ordered by frequency of response in
Table V. The most commonly mentioned advantage was the ability
of the test to identify and pinpoint when ovulation occurs and this
was linked by the volunteers to the increased likelihood of getting
pregnant. It was also observed that using the ovulation tests helped
the users to focus their conception attempts to the correct time in
their cycle, one volunteer saying that she felt she would be doing
something psychologically proactive. The main response when asked
about disadvantages was that there were none; however, other disad-
vantages included added pressure on the partner and a lack of spon-
taneity associated with timing intercourse, although this was often
countered by the desire to achieve a pregnancy.
Discussion
This study used three different tools to assess levels of stress in
women attempting to conceive outside of any fertility investigations;
validated questionnaire, urinary biomarkers and qualitative information
collected by interview. We found no difference either in the
Figure 4 Loadings plot based on PCA ﬁtted to all the data including all the questionnaires, biochemical markers and demographic characteristics.
Principal component 1 (x-axis) relates to the trends observed between the positive and negative questions/responses from the PANAS and PSS ques-
tionnaires and principal component 2 (y-axis) is related to the positive and negative questions/responses from the SF-12 questionnaire. Two measure-
ments that are close to each other are positively correlated and measurements that are diagonally opposite each other are negatively correlated. Clear
separation is evident between the positive and negative responses to the PANAS questionnaire (purple and yellow dots, respectively) and to the PSS
questionnaire as depicted by the two populations of orange dots observed. Bioc: Biochemistry marker, Demo: Demographic characteristic, Pos: Posi-
tive and Negative Affect Schedule (PANAS) Positive affect, Neg: PANAS: Negative affect, PSS: Perceived Stress Scale (PSS) Total Stress, Ment: Short
Form 12 (SF12) Mental, Phys: SF12 Physical, SF12 Total score. On graph: Individual questions colour coded according to questionnaire, otherwise as
indicated, Try Conceive: length in time trying to conceive (months), Pre-Study: length of pre-study period (days), BMI; Body Mass Index, Cre: Cre-
atinine (g/dl), Cor: Cortisol (mg/dl), E3G: Estrone-3-Glucuronide (ng/ml), ECR: E3G:Creatinine ratio, CCR: Cortisol:Creatinine ratio.
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questionnaire results or in the biomarker analysis between levels of
stress in the women who were using the ovulation tests compared
with the control group who were not using any methods to try and
identify when they were ovulating. This indicates that use of the
digital ovulation test in couples who are trying to conceive should
not be dismissed with the presumption that they cause stress.
The questionnaire results for all tools over the duration of the study
remained relatively ﬂat and results were comparable with the pub-
lished normative data in female populations. The similarity in the
SF-12 data between the two groups at baseline and at the end of
the study is particularly encouraging as it suggests that the general well-
being of participants who did not become pregnant in both groups was
similar and did not change over the duration of the study. The results
of this study can be applied to the cohort of women recruited, i.e.
those that have no known evidence of infertility and who are
looking to conceive in a non-medical setting. A separate study
would be needed to assess whether the same can be said for
women who have been trying to conceive for many months and
who may be attending a fertility clinic, as psychological stress in this
group of women is likely to be quite different.
Emotional distress such as tension and worry is often portrayed as a
contributing factor in failing to conceive quickly; however, the evidence
is somewhat inconclusive. This notion is often based on anecdotal evi-
dence of natural conceptions after adoption or holidays. There is
some evidence to suggest that psychological distress may be a risk
factor for reduced fertility in women, particularly in those with long
menstrual cycles (Takefman et al., 1990; Sanders and Bruce, 1997;
Hjollund et al., 1999).
A recent study of women trying to conceive from the general popu-
lation found that those with the highest quartile of salivary a-amylase
concentration had slightly lower day-speciﬁc probabilities of concep-
tion but this was apparent only in the ﬁrst cycle (Buck-Louis et al.,
2011). A further publication, based on the same study population,
showed no relationship between pregnancy and self-reported psycho-
logical stress as measured by questionnaires on Day 6 of the menstrual
cycle (Lynch et al., 2012).
A recent meta-analysis by Boivin et al. (2011) of 14 prospective
studies looking at the association between emotional distress and
pregnancy in women undergoing a single cycle of assisted reproductive
technology indicated a lack of association between emotional distress
(e.g. feelings of tension, nervousness or worry) and pregnancy
outcome. Other studies have also shown little or no effect of stress
on pregnancy outcome (Milad et al., 1998; Sheiner et al., 2003; Ander-
heim et al., 2005). Our study results support the latter view as levels of
Figure 5 Loadings plot based on PCA ﬁtted to all the data except individual questions and focusing on biochemical markers. Principal component 1
(x-axis) relates to the stress score and principal component 2 (y-axis) relates to the correlations between biochemical markers. Two measurements
that are close to each other are positively correlated and measurements that are diagonally opposite each other are negatively correlated. The bio-
chemistry data (green dots) are grouped close to the centre of the plot showing that there is no clear separation either between the two random-
ization groups or between the study outcomes. Bioc: Biochemistry marker, Demo: Demographic characteristic, Pos: Positive and Negative Affect
Schedule (PANAS) Positive affect, Neg: PANAS: Negative affect, PSS: Perceived Stress Scale (PSS) Total Stress, Ment: Short Form 12 (SF12)
Mental, Phys: SF12 Physical, SF12 Total score. On graph: Tot: Total score colour coded according to questionnaire, otherwise as indicated, Try Con-
ceive: length in time trying to conceive (months), Pre-Study: length of pre-study period (days), BMI; Body Mass Index, Cre: Creatinine (g/dl), Cor:
Cortisol (mg/dl), E3G: Estrone-3-Glucuronide (ng/ml), ECR: E3G:Creatinine ratio, CCR: Cortisol:Creatinine ratio.
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stress were found to be unrelated to pregnancy outcome, or indeed,
affected by emotional factors such as number of previous miscarriages
or length of time trying to conceive.
The potential effect of stress on pregnancy outcome is important as
current guidelines suggest that ovulation tests can increase stress in
women who are trying to conceive. The only study to date that spe-
ciﬁcally addresses this question is that by Kopitzke et al. (1991). Retro-
spective studies such as that used to support the NICE guidelines
(Kopitzke et al., 1991), which measure stress when the outcome of
the treatment is already known, may affect the participants’ view of
the level of stress they experienced (Boivin and Takefman, 1995). Pro-
spective studies such as ours are likely to provide a more accurate ap-
preciation of levels of stress in real time. Owing to the parity of data
and plethora of opinion in this area, we believe that our study is ex-
tremely important as it provides new evidence that the use of digital
ovulation tests by women outside of fertility clinics does not cause
stress. Published evidence also suggests that there are likely to be
far more stressful experiences while trying to conceive than timing
of intercourse alone (Connolly et al., 1993; Boivin and Takefman,
1995; Boivin and Lancastle, 2010).
Although the number of pregnancies in this study was found to be
higher in women who were using digital ovulation tests, the study was
inadequately powered to compare the two groups with respect to con-
ception. We can conclude that use of ovulation tests does not have a
detrimental effect on time to conception. We suggest that a further
study of more women over a longer period of time would be useful in
assessing the effect of digital ovulation tests on conception rates.
Much of the data available for ovulation tests currently focus on the ac-
curacy of the tests rather than efﬁcacy except for one study of a fertility
monitor (which has an ovulation test component) reporting it to be
associated with an increased pregnancy rate (Robinson et al., 2007).
This adds weight to the argument that factors such as mistiming of inter-
course, increasing age of womenwho are trying to conceive and a lack of
knowledge of the menstrual cycle and cycle length are more likely than
increased levels of stress, to affect the chances of conception in any given
cycle (Robinson and Ellis, 2007; Zinaman et al., 2012).
.............................................................................................................................................................................................
Table IV Qualitative data—responses to closed questions from the exit interview.
Question Response Test (%),
(n5 15)
Control (%),
(n 5 15)
How long did you expect it would take you to conceive? ≤3 months 1 (7) 3 (20)
≤6 months 4 (27) 2 (13.3)
≤12 months 0 (0) 0 (0)
≤24 months 1 (7) 2 (13.3)
Do not know 4 (26) 6 (40)
Not long/quickly 5 (33) 2 (13.3)
Before joining the study did you think you knew when you were ovulating? Yes 4 (27) 6 (40)
No 11 (73) 9 (60)
Have you ever used any method for determining when ovulation occurs? Yes 7 (47) 8 (53)
No 7 (47) 7 (47)
Not asked 1 (7) 0 (0)
Do you feel any pressure or stress during your cycle? Yes 2 (13) 10 (67)
No 3 (20) 4 (26)
Work/family bereavement 2 (13) 1 (7)
Miscarriage 1 (7) 0 (0)
Not asked 7 (47) 0 (0)
Does the prospect of testing for ovulation appeal to you? Yes 15 (100) 15 (100)
No 0 (0) 0 (0)
Did you follow the NICE guidelines for achieving conception while on the
study?
Yes/aware — 12 (80)
No — 3 (20)
Did the ovulation test meet your expectations when you used it? Yes 14 (93) —
No 1 (7) —
Was the product easy to use? Yes 15 (100) —
No 0 (0) —
Did using the test help you to notice any changes occurring in your body
during your cycle?
Yes 8 (53) —
No 3 (20) —
Not asked 4 (27) —
Did you feel any pressure or stress when using the test? Yes (1 due to work/1 lack of test
sticks)
7 (47) —
No 8 (53) —
Will you consider purchasing this product in the future? Yes 13 (86) —
No 1 (7) —
Possibly (as other arrangements
with GP)
1 (7) —
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For a number of years, women across Europe and other developed
nations have been postponing parenthood (Mathews and Hamilton,
2009). According to recent population statistics in the UK, over the
past 20 years (1990–2010), there has been a clear shift in the total
number of live births to increased age of mother (ONS, 2010). It
has also been shown that the monthly chance of achieving a clinical
pregnancy or live birth starts declining in the late 20s for women,
with a substantial decline by the late 30s (Schmidt et al., 2011). As
a consequence, an increasing proportion of couples are experiencing
infertility and prolonged time to pregnancy as well as a range of
adverse pregnancy outcomes. These facts coupled with the modern-
day desire and expectation that getting pregnant is something that
should happen quickly and easily mean that more women are
looking for tools that can help them achieve their goal. In our study,
over half of the volunteers expected to conceive within 6 months of
starting to try. However, because many women have a limited under-
standing of their own fertility (Small et al., 2007) and start their families
later in life, getting pregnant can often take longer than expected.
The qualitative aspect of this study has highlighted a number of
other positive beneﬁts of using the digital ovulation test which for
some women was very helpful. These include a sense of empower-
ment, and a feeling of comfort and reassurance that the test can
show a surge in LH occurs and that intercourse can be focused to
the right time of the cycle.
There may also be value in knowing early whether or not a surge in
LH is occurring as it may be a trigger for seeking medical advice
sooner. In many cases, particularly in older women, fertility advice is
often not sought early enough. In fact, ,55% of subfecund women
have been shown to seek medical advice and treatment at all
(Boivin et al., 2007). A study by Bunting and Boivin (2007) showed
that often this is related to a fear of discovering a problem and
these negative reactions can substantially delay seeking help in 20%
of women. It is of interest that a proportion (14%) of the volunteers
in our study had been trying to conceive for longer than 12 months as
by deﬁnition, infertility is the inability to conceive after 12 months of
unprotected intercourse (ASRM, 2006). This may be a reﬂection of
the type of women in the UK population with possible fertility pro-
blems who do not seek medical advice when perhaps they should.
Use of digital ovulation tests in the early attempts at conception
may prompt women who do not detect the LH surge to seek help
earlier than they otherwise would.
The variation in the E3G results on the surge day of both cycles was
found to be larger in both the test and the control groups, probably
because the collection of this sample was timed to the day of the
LH surge, where estrogen concentration is also variable. In addition,
the E3G: creatinine ratio was higher in the test group compared
with the control group, probably because the collection of this
sample was timed to the day of the LH surge, where urinary E3G
is also maximal. For the control group, timing was assigned on
the basis of self-reported average cycle length. This method pro-
vides much less accurate timing, so for many volunteers in the
control group this did not correspond to the day of maximal
urinary E3G. This shows that identiﬁcation of peak fertility based
on menstrual cycle characteristics and self-reported cycle length
is not reliable.
A potential ﬂaw in this study is that we saw an unexpectedly high
pregnancy rate in the test group including a large number of pregnan-
cies before the start of the study, and therefore, to reduce any weak-
ness in the study population, we implemented an additional bias
recruitment to ensure that there was a representative sample of
test users who did not achieve a pregnancy at the end of the study.
Although no signiﬁcant differences were observed between the two
phases of recruitment for any of the demographic information, there
is a possibility that the second cohort of volunteers may have slightly
different baseline characteristics. It is possible, for example, that the
second recruitment phase may include those that were unsuccessful
in the ﬁrst phase and therefore may have been trying to conceive
for a longer length of time.
This study did not observe the effect of use of the ovulation test on
male partners. Several studies have shown that timed intercourse as
required in early-fertility investigations for the post-coital test, for
example, may increase emotional distress or cause sexual dysfunction
in men (Drake and Grunert, 1979; Takefman et al., 1990; Boivin et al.,
1992). Further studies of men examining the effect of timed inter-
course using ovulation tests would be interesting using the same ana-
lysis tools used here.
A further research question would be whether or not use of home
ovulation tests can inﬂuence the behaviour of couples in focusing inter-
course to the fertile period by collecting data on timing and frequency
........................................................................................
Table V Summary of actual (test group) and perceived
(control group) advantages and disadvantages of
ovulation test use by randomization group.
Test group Control group
Advantages
Timing/pinpoint of ovulation Timing/pinpoint ovulation
Ability to plan Removes uncertainty
Easy to use Easy to use
Relaxes/stress free/puts mind at
ease
Know that you get a surge on a
regular basis
Takes pressure off reading
body/scientiﬁc
Very straight forward/clear
Learn about cycle Convenience/keep focused
Improves chances of pregnancy Psychologically proactive
Accuracy/very clear Smiley face, not line
Know where in cycle if irregular
Disadvantages
None (33%) None (33%)
Added pressure/pressure on
partner
Knew optimum time so why not
happening
Removes fun factor spontaneity/
could get obsessed
Could get emotionally dependent
Having to test same time every
day
Involvement/cannot take away on
holiday/regimental
Distressing if calendar says
ovulating but not
Costly. Likely to deter from
intercourse
Gutted to see surge as partner
was away
Process functional/pressure
Themes have been ordered by frequency of response.
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of intercourse. However, this type of information is difﬁcult to collect
accurately and can make participation over-cumbersome for the
volunteers taking part with risk to overall study compliance and its in-
clusiveness to volunteers.
In summary, this study has shown that there is no difference in levels
of stress between women using home ovulation tests and women who
are trying to conceive having been provided with the NICE guidelines
on increasing the chances of conception. The suggested beneﬁts of use
of home ovulation detection kits include possible reduction in time to
pregnancy, improved understanding of ovarian and menstrual cycles
and positive reinforcement of reproductive health. Women who
wish to use these tests as an aid to conception should not be discour-
aged because of unfounded suggestions that they increase stress levels
among users.
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